Schrodinger Analyst Ratings
Buy Rating for Arcturus Therapeutics: Advancing Clinical Programs and Strengthening Safety Profile
Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Arcturus Therapeutics Analyst Ratings
Buy Rating Affirmed: Promising Developments in Arcturus Therapeutics' MRNA Treatments for Rare Diseases
Twist Bioscience Analyst Ratings
Nurix Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Ionis Pharmaceuticals Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Recursion Pharmaceuticals Analyst Ratings
Intellia Therapeutics Analyst Ratings
Intellia Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $26
Nurix Therapeutics Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Ionis Pharmaceuticals Analyst Ratings
Twist Bioscience Analyst Ratings
Nurix Therapeutics Analyst Ratings